Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 228

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 228
---
000 to the Representative, which will be applied against the Representative’s actual out-of-pocket accountable expenses
that are payable by us in connection with this offering and such expense deposit shall be reimbursed to the Company to the extent any
portion thereof is not actually incurred in compliance with FINRA Rule 5110(g)(4)(A). We have agreed to reimburse the Representative
for the fees and expenses of its legal counsel in connection with the offering in an amount not to exceed $125,000, the fees and expenses
related to the use of Ipreo’s book building, prospectus tracking and compliance software for the offering in the amount of $29,500,
up to $15,000 for background checks of our officers and directors, the costs associated with bound volumes of the public offering materials
as well as commemorative mementos and lucite tombstones in an amount not to exceed $3,000, data services and communications expenses
up to $10,000, the actual accountable “road show” expenses up to $10,000 and the costs of market making and trading and clearing
firm settlement expenses up to $30,000; provided however that the aggregate accountable expenses reimbursement will not exceed $175,000.

We expect that the expenses
of this offering payable by us, not including underwriting discounts and commissions, will be approximately $1,000,000.

Representative’s Warrants

We have agreed to issue to
the Representative, upon the consummation of this offering, warrants to purchase up to an aggregate amount of Ordinary Shares equal to
an aggregate of up to (representing 5.0% of the Ordinary Shares sold in this offering, including any Ordinary Shares sold upon exercise
of the Representative’s over-allotment option), or the Representative’s Warrants. The Representative’s Warrants are
exercisable at a per share price equal to $ (representing 125.0% of the public offering price
per share in this offering). The Representative’s Warrants are exercisable at any time and from time to time, in whole or in part,
during the four and one-half (4.5) year period commencing 180 days from the commencement of sales of the securities in this offering.
The Representatives Warrants will provide for registration rights (including a one-time demand registration right and unlimited piggyback
rights) and customary anti-dilution provisions (for stock dividends and splits and recapitalizations) consistent with FINRA Rule 5110,
and further